JP2015530888A - 対象のモニタリングと表面処理のためのシステムおよび方法 - Google Patents
対象のモニタリングと表面処理のためのシステムおよび方法 Download PDFInfo
- Publication number
- JP2015530888A JP2015530888A JP2015521766A JP2015521766A JP2015530888A JP 2015530888 A JP2015530888 A JP 2015530888A JP 2015521766 A JP2015521766 A JP 2015521766A JP 2015521766 A JP2015521766 A JP 2015521766A JP 2015530888 A JP2015530888 A JP 2015530888A
- Authority
- JP
- Japan
- Prior art keywords
- sensor
- matrix
- analyte
- therapeutic agent
- dressing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 39
- 238000012544 monitoring process Methods 0.000 title description 14
- 238000004381 surface treatment Methods 0.000 title 1
- 239000011159 matrix material Substances 0.000 claims abstract description 78
- 239000012491 analyte Substances 0.000 claims abstract description 36
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract description 20
- -1 hydrogen ions Chemical class 0.000 claims abstract description 13
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims abstract description 11
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Natural products O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000001569 carbon dioxide Substances 0.000 claims abstract description 8
- 229910002092 carbon dioxide Inorganic materials 0.000 claims abstract description 8
- 229910001882 dioxygen Inorganic materials 0.000 claims abstract description 8
- 239000001257 hydrogen Substances 0.000 claims abstract description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 121
- 229940124597 therapeutic agent Drugs 0.000 claims description 107
- 238000011282 treatment Methods 0.000 claims description 62
- 229920000642 polymer Polymers 0.000 claims description 35
- 230000003993 interaction Effects 0.000 claims description 24
- 230000001225 therapeutic effect Effects 0.000 claims description 23
- 230000004044 response Effects 0.000 claims description 22
- 230000007246 mechanism Effects 0.000 claims description 18
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 13
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 13
- 150000004032 porphyrins Chemical class 0.000 claims description 13
- 238000010521 absorption reaction Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 6
- 239000000090 biomarker Substances 0.000 claims description 3
- 230000005672 electromagnetic field Effects 0.000 claims description 3
- 238000004891 communication Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims 2
- 229940039227 diagnostic agent Drugs 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 1
- 238000013461 design Methods 0.000 abstract description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 68
- 239000001301 oxygen Substances 0.000 description 68
- 229910052760 oxygen Inorganic materials 0.000 description 68
- 210000001519 tissue Anatomy 0.000 description 61
- 206010052428 Wound Diseases 0.000 description 54
- 208000027418 Wounds and injury Diseases 0.000 description 54
- 239000010410 layer Substances 0.000 description 29
- 210000003491 skin Anatomy 0.000 description 23
- 230000001684 chronic effect Effects 0.000 description 19
- 239000000463 material Substances 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- 238000013459 approach Methods 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 238000007726 management method Methods 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 238000005259 measurement Methods 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 229940126585 therapeutic drug Drugs 0.000 description 13
- 238000001514 detection method Methods 0.000 description 12
- 238000009792 diffusion process Methods 0.000 description 11
- 210000000434 stratum corneum Anatomy 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 230000001154 acute effect Effects 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 230000035699 permeability Effects 0.000 description 9
- 230000029663 wound healing Effects 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- KQIADDMXRMTWHZ-UHFFFAOYSA-N chloro-tri(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)C(C)C KQIADDMXRMTWHZ-UHFFFAOYSA-N 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 229960005486 vaccine Drugs 0.000 description 8
- 239000000412 dendrimer Substances 0.000 description 7
- 229920000736 dendritic polymer Polymers 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 238000005286 illumination Methods 0.000 description 7
- 239000002105 nanoparticle Substances 0.000 description 7
- 239000003504 photosensitizing agent Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000005538 encapsulation Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000005284 excitation Effects 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 230000035515 penetration Effects 0.000 description 6
- 229920000193 polymethacrylate Polymers 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 5
- 229940035676 analgesics Drugs 0.000 description 5
- 239000000730 antalgic agent Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 238000006213 oxygenation reaction Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 230000005281 excited state Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000000017 hydrogel Substances 0.000 description 4
- 230000036512 infertility Effects 0.000 description 4
- 230000002452 interceptive effect Effects 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 230000002980 postoperative effect Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 150000003852 triazoles Chemical class 0.000 description 4
- 208000004210 Pressure Ulcer Diseases 0.000 description 3
- QYNCZLPRFXWLEN-UHFFFAOYSA-N [9-(diethylamino)benzo[a]phenothiazin-5-ylidene]-ethylazanium;chloride Chemical compound [Cl-].C12=CC=CC=C2C(=[NH+]CC)C=C2C1=NC1=CC=C(N(CC)CC)C=C1S2 QYNCZLPRFXWLEN-UHFFFAOYSA-N 0.000 description 3
- 239000012790 adhesive layer Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000013500 data storage Methods 0.000 description 3
- 238000001804 debridement Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000007933 dermal patch Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 230000002186 photoactivation Effects 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- GEVPIWPYWJZSPR-UHFFFAOYSA-N tcpo Chemical compound ClC1=CC(Cl)=CC(Cl)=C1OC(=O)C(=O)OC1=C(Cl)C=C(Cl)C=C1Cl GEVPIWPYWJZSPR-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 208000005230 Leg Ulcer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- NPRDEIDCAUHOJU-UHFFFAOYSA-N [Pt].N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 Chemical class [Pt].N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 NPRDEIDCAUHOJU-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 2
- 229960002428 fentanyl Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000004868 gas analysis Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 238000013532 laser treatment Methods 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 238000002428 photodynamic therapy Methods 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 238000009827 uniform distribution Methods 0.000 description 2
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 2
- DMLAVOWQYNRWNQ-YPKPFQOOSA-N (Z)-azobenzene Chemical compound C1=CC=CC=C1\N=N/C1=CC=CC=C1 DMLAVOWQYNRWNQ-YPKPFQOOSA-N 0.000 description 1
- CQVWXNBVRLKXPE-UHFFFAOYSA-N 2-octyl cyanoacrylate Chemical compound CCCCCCC(C)OC(=O)C(=C)C#N CQVWXNBVRLKXPE-UHFFFAOYSA-N 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- JFZHPFOXAAIUMB-UHFFFAOYSA-N Phenylethylmalonamide Chemical compound CCC(C(N)=O)(C(N)=O)C1=CC=CC=C1 JFZHPFOXAAIUMB-UHFFFAOYSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010053692 Wound complication Diseases 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- FAMPSKZZVDUYOS-UHFFFAOYSA-N alpha-Caryophyllene Natural products CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 description 1
- 229940072049 amyl acetate Drugs 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- PGMYKACGEOXYJE-UHFFFAOYSA-N anhydrous amyl acetate Natural products CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940117948 caryophyllene Drugs 0.000 description 1
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940125368 controlled substance Drugs 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 125000002573 ethenylidene group Chemical group [*]=C=C([H])[H] 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000001465 metallisation Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920001483 poly(ethyl methacrylate) polymer Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000000287 tissue oxygenation Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0015—Phosphorescence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/683—Means for maintaining contact with the body
- A61B5/6832—Means for maintaining contact with the body using adhesives
- A61B5/6833—Adhesive patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
- A61B5/14552—Details of sensors specially adapted therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
- A61B5/14556—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases by fluorescence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
- A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
- A61B5/443—Evaluating skin constituents, e.g. elastin, melanin, water
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/12—Manufacturing methods specially adapted for producing sensors for in-vivo measurements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0015—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by features of the telemetry system
- A61B5/0022—Monitoring a patient using a global network, e.g. telephone networks, internet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/742—Details of notification to user or communication with user or patient ; user input means using visual displays
- A61B5/743—Displaying an image simultaneously with additional graphical information, e.g. symbols, charts, function plots
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00902—Plasters containing means
- A61F2013/0094—Plasters containing means for sensing physical parameters
- A61F2013/0097—Plasters containing means for sensing physical parameters oxygen content
Abstract
Description
Claims (25)
- 分子酸素、二酸化炭素、窒素酸化物、血漿および組織中に溶解した検体、および水素イオンからなる群から選ばれる検体の濃度を検出するセンサ、
前記センサと互換性のマトリックスであり、前記マトリックスの少なくとも一部が前記検体に、少なくともアクセス可能か透過性があるマトリックス、及び
前記マトリックスと前記センサを含むドレッシングを含む装置であって、
前記装置が、燐光、蛍光、及び吸収の少なくとも一つを含む電磁場の非弾性散乱を調整することにより、前記センサによって検出される前記検体の濃度に応答して信号を発することを特徴とする装置。 - 前記センサが、患者の組織表面と相互作用するように構成される請求項1に記載の装置。
- 前記ドレッシングが、剥離可能に患者の組織表面に貼付される請求項1に記載の装置。
- 前記センサが、メソ非置換ポルフィリンを含む請求項1に記載の装置。
- さらに、治療薬、バイオマーカー、及び患者の組織表面への診断剤の少なくとも一つを送達するように構成される治療部位を含む請求項1に記載の装置。
- 前記治療部位が、さらに患者の組織表面に治療薬を放出するように構成される作動治療薬放出機構の少なくとも1つを含む請求項5に記載の装置。
- 前記作動治療薬放出機構が、前記信号に応答するように構成される光作動性ポリマーマトリックスを含む請求項6に記載の装置。
- 前記ポリマーマトリックスが、ポリジメチルシロキサン(PDMS)を含む請求項7に記載の装置。
- さらに、前記検体に関連するパラメータのアクティブなリアルタイムマップを形成するように構成される表示機構を含む請求項7に記載の装置。
- (a)分子酸素、二酸化炭素、窒素酸化物、血漿及び組織中に溶解した検体、及び水素イオンの少なくとも一つを含む検体の濃度を検出するセンサを選択する工程、
(b)前記センサの化学的性質に基づいて互換性のマトリックスを選択する工程、
(c)少なくとも一部が前記検体にアクセス可能な前記互換性マトリックスに前記センサを巻き込む工程、及び
(d)前記マトリックスをドレッシングに組み込む工程
を含む検体を検出するための装置を製造する方法であって、
前記ドレッシングが、前記センサによって検出される前記検体の濃度に応答して信号を発するように構成されることを特徴とする装置の製造方法。 - 前記センサが、患者の組織表面と相互作用するように構成される請求項10に記載の方法。
- 前記センサが、メソ非置換メタル化ポルフィリンを含む、請求項10に記載の方法。
- さらに、治療薬、バイオマーカー、及び患者の組織表面への診断剤の少なくとも一つを送達するように構成される治療部位を含む請求項10に記載の方法。
- さらに、前記検体に関連するパラメータのアクティブなリアルタイムマップを形成するように構成される表示機構を含む請求項10に記載の方法。
- 少なくとも1つの検体を検出するように構成されたセンサを備えるドレッシングと前記センサとの互換性マトリックス、及び
前記センサを作動させ、前記ドレッシングの表面及び内部の少なくとも一方の位置の関数としての信号を測定するように構成した検出器であって、前記信号が、前記ドレッシングの表面に近接する少なくとも一つの前記検体に応答し、電磁場の非弾性散乱の変調によって生成されることを特徴とする検体の検出用キット。 - 前記センサは、患者の組織表面と相互作用するように構成されることを特徴とする請求項15に記載のキット。
- 前記センサはメソ非置換メタル化ポルフィリンを含む、請求項15に記載のキット。
- さらに、患者の組織表面に治療薬を送達するように構成された治療部位を含む、請求項15に記載のキット。
- 前記治療部位は、外部システム、ネットワーク、またはコンピュータとのローカル及び/又はリモートの通信が可能であることを特徴とする請求項18に記載のキット。
- さらに、前記センサ及び前記治療部位のうちの少なくとも一方を作動させるように構成された相互作用部分を含む、請求項18に記載のキット。
- さらに、前記検体に関連するパラメータのアクティブなリアルタイムマップを形成するように構成された表示機構をさらに備える、請求項15に記載のキット。
- 前記検出器は、前記ドレッシング及び周辺環境の少なくとも一つから放出される信号を引き出すように構成されていることを特徴とする請求項15に記載のキット。
- 前記検出器は、さらに濃度を含む検体の特性を報告するように構成される請求項15に記載のキット。
- 前記検出器はさらに、ネットワーク、ディスプレイ、及びコンピュータシステムの少なくとも一つと通信するように構成されることを特徴とする請求項15に記載のキット。
- 前記ドレッシングは、患者の組織表面に液体として適用され、その患者の組織表面上に固体を形成するように構成される請求項15に記載のキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261669718P | 2012-07-10 | 2012-07-10 | |
US61/669,718 | 2012-07-10 | ||
PCT/US2013/049847 WO2014011724A1 (en) | 2012-07-10 | 2013-07-10 | System and method for monitoring and treating a surface of a subject |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015530888A true JP2015530888A (ja) | 2015-10-29 |
JP6321004B2 JP6321004B2 (ja) | 2018-05-09 |
Family
ID=49916522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015521766A Active JP6321004B2 (ja) | 2012-07-10 | 2013-07-10 | 対象のモニタリングと表面処理のためのシステムおよび方法 |
Country Status (7)
Country | Link |
---|---|
US (5) | US10016164B2 (ja) |
EP (1) | EP2872877B1 (ja) |
JP (1) | JP6321004B2 (ja) |
DK (1) | DK2872877T3 (ja) |
ES (1) | ES2957540T3 (ja) |
FI (1) | FI2872877T3 (ja) |
WO (1) | WO2014011724A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016090505A (ja) * | 2014-11-10 | 2016-05-23 | 国立大学法人横浜国立大学 | センサー装置、生体分子視覚化装置およびセンシング方法 |
JP2017181211A (ja) * | 2016-03-29 | 2017-10-05 | 株式会社カテラ | 光学的経皮酸素センサ及びこれを用いた経皮酸素濃度測定装置 |
JP2019520114A (ja) * | 2016-05-13 | 2019-07-18 | ザ ジェネラル ホスピタル コーポレイション | 光経皮酸素モニタリングのシステム及び方法 |
KR20220029073A (ko) * | 2020-09-01 | 2022-03-08 | (주) 에이슨 | 유연 경피성 산소 분압센서 |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2872877B1 (en) | 2012-07-10 | 2023-05-24 | The General Hospital Corporation | System and method for monitoring and treating a surface of a subject |
GB201317746D0 (en) | 2013-10-08 | 2013-11-20 | Smith & Nephew | PH indicator |
US9789206B2 (en) | 2013-07-10 | 2017-10-17 | The General Hospital Corporation | Compounds, systems, and methods for monitoring and treating a surface of a subject |
ES2860675T3 (es) * | 2013-07-10 | 2021-10-05 | Massachusetts Gen Hospital | Compuestos, sistemas y métodos para monitorizar y tratar una superficie de un sujeto |
WO2015163957A2 (en) * | 2014-01-31 | 2015-10-29 | The General Hospital Corporation | System and method for photoluminescence detection |
JP2016090312A (ja) * | 2014-10-31 | 2016-05-23 | 株式会社島津製作所 | 酸素濃度計測シール及びそれが用いられた燃料電池セル |
GB201600746D0 (en) | 2016-01-14 | 2016-03-02 | Smith & Nephew | Improvements in and relating to polymer materials |
GB201600747D0 (en) | 2016-01-14 | 2016-03-02 | Smith & Nephew | Improvements in and relating to devices |
EP3454809B8 (en) * | 2016-05-10 | 2020-12-30 | 3M Innovative Properties Company | Flexible means for determining the extent of debridement required to remove non-viable tissue |
JP2019527566A (ja) | 2016-05-13 | 2019-10-03 | スミス アンド ネフュー ピーエルシーSmith & Nephew Public Limited Company | センサが使用可能な創傷監視および治療装置 |
WO2018162736A1 (en) | 2017-03-09 | 2018-09-13 | Smith & Nephew Plc | Wound dressing, patch member and method of sensing one or more wound parameters |
US11324424B2 (en) | 2017-03-09 | 2022-05-10 | Smith & Nephew Plc | Apparatus and method for imaging blood in a target region of tissue |
SG11201909449TA (en) | 2017-04-11 | 2019-11-28 | Smith & Nephew | Component positioning and stress relief for sensor enabled wound dressings |
CN110832598B (zh) | 2017-05-15 | 2024-03-15 | 史密夫及内修公开有限公司 | 伤口分析装置和方法 |
AU2018288530B2 (en) | 2017-06-23 | 2024-03-28 | Smith & Nephew Plc | Positioning of sensors for sensor enabled wound monitoring or therapy |
GB201804502D0 (en) | 2018-03-21 | 2018-05-02 | Smith & Nephew | Biocompatible encapsulation and component stress relief for sensor enabled negative pressure wound therapy dressings |
GB201809007D0 (en) | 2018-06-01 | 2018-07-18 | Smith & Nephew | Restriction of sensor-monitored region for sensor-enabled wound dressings |
US11925735B2 (en) | 2017-08-10 | 2024-03-12 | Smith & Nephew Plc | Positioning of sensors for sensor enabled wound monitoring or therapy |
JP2020533093A (ja) | 2017-09-10 | 2020-11-19 | スミス アンド ネフュー ピーエルシーSmith & Nephew Public Limited Company | 封入を検査するためのシステムおよび方法、ならびにセンサを装備した創傷被覆材内の構成要素 |
GB201804971D0 (en) | 2018-03-28 | 2018-05-09 | Smith & Nephew | Electrostatic discharge protection for sensors in wound therapy |
GB201718870D0 (en) | 2017-11-15 | 2017-12-27 | Smith & Nephew Inc | Sensor enabled wound therapy dressings and systems |
GB201718859D0 (en) | 2017-11-15 | 2017-12-27 | Smith & Nephew | Sensor positioning for sensor enabled wound therapy dressings and systems |
US11596553B2 (en) | 2017-09-27 | 2023-03-07 | Smith & Nephew Plc | Ph sensing for sensor enabled negative pressure wound monitoring and therapy apparatuses |
EP3687396A1 (en) | 2017-09-28 | 2020-08-05 | Smith & Nephew plc | Neurostimulation and monitoring using sensor enabled wound monitoring and therapy apparatus |
JP2021502845A (ja) | 2017-11-15 | 2021-02-04 | スミス アンド ネフュー ピーエルシーSmith & Nephew Public Limited Company | 統合センサ対応型創傷モニタリングおよび/または治療被覆材ならびにシステム |
CN108827480B (zh) * | 2018-04-11 | 2020-03-27 | 山东师范大学 | 一种基于磷光发射的抗氧干扰温度传感器 |
GB2592508B (en) | 2018-09-12 | 2022-08-31 | Smith & Nephew | Device, apparatus and method of determining skin perfusion pressure |
JP2020071152A (ja) * | 2018-10-31 | 2020-05-07 | ソニー株式会社 | 免疫染色方法、免疫染色システム、および免疫染色キット |
US20200392378A1 (en) * | 2019-06-17 | 2020-12-17 | Richard William Schofield | Adhesive tape with strip to help locate and lift the leading edge, and methods of manufacturing same |
KR20220098147A (ko) * | 2019-10-17 | 2022-07-11 | 씨2센스, 인크. | 감지 및/또는 인증을 위한 발광 이미징 |
KR20220098146A (ko) * | 2019-10-17 | 2022-07-11 | 씨2센스, 인크. | 감지를 위한 발광 이미징 |
CN111135341B (zh) * | 2020-01-20 | 2021-10-29 | 浙江大学 | 一种用于感染创面预警和可控治疗的智能水凝胶敷料 |
US11788925B1 (en) * | 2020-02-11 | 2023-10-17 | Ironhawk Industrial Distribution LLC | Monitoring system for a component in a cutting edge |
WO2022266070A1 (en) | 2021-06-14 | 2022-12-22 | Preh Holding, Llc | Connected body surface care module |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH067423A (ja) * | 1992-03-12 | 1994-01-18 | Atrix Lab Inc | 生分解性フィルム被覆材及びその製造方法 |
JP2000292354A (ja) * | 1999-03-29 | 2000-10-20 | Avl Medical Instr Ag | 局所的な測定量の分布を定量的に測定するための装置 |
JP2000517417A (ja) * | 1996-07-22 | 2000-12-26 | ノバルティス アクチエンゲゼルシャフト | 酸素オプトロードのための光感受性組成物 |
JP2003516795A (ja) * | 1999-12-14 | 2003-05-20 | エフ・ホフマン・ラ・ロッシュ・アー・ゲー | 測定パラメータの局所的分布を測定するための方法および装置 |
JP2005501256A (ja) * | 2001-08-22 | 2005-01-13 | スリーエム イノベイティブ プロパティズ カンパニー | 蛍光ベースの酸素センサシステム |
JP2009506878A (ja) * | 2005-09-07 | 2009-02-19 | タイコ ヘルスケア グループ リミテッド パートナーシップ | マイクロポンプを有する自蔵創傷手当て |
WO2012010238A1 (en) * | 2010-07-17 | 2012-01-26 | Merck Patent Gmbh | Enhancement of penetration and action |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU605331B2 (en) * | 1987-06-01 | 1991-01-10 | Dow Chemical Company, The | Process for making propargyl ethers of hydroxyaromatic compounds |
US4840796A (en) * | 1988-04-22 | 1989-06-20 | Dow Corning Corporation | Block copolymer matrix for transdermal drug release |
US6362175B1 (en) | 1991-09-20 | 2002-03-26 | The Trustees Of The University Of Pennsylvania | Porphyrin compounds for imaging tissue oxygen |
US5837865A (en) | 1993-10-15 | 1998-11-17 | Trustees Of The University Of Pennsylvania | Phosphorescent dendritic macromolecular compounds for imaging tissue oxygen |
WO1997019188A1 (en) | 1995-11-22 | 1997-05-29 | Minimed, Inc. | Detection of biological molecules using chemical amplification and optical sensors |
DE69634265T2 (de) * | 1995-12-19 | 2006-04-27 | Abbott Laboratories, Abbott Park | Vorrichtung zum detektieren eines analyten und zur verabreichung einer therapeutischen substanz |
EP0915883B1 (en) | 1996-07-22 | 2002-04-03 | Novartis AG | Process for the preparation of platinum or palladium benzoporphyrins and platinum or palladium cyclohexenoporphyrins, intermediates, and an oxygen sensor comprising platinum or palladium cyclohexenoporphyrin |
US20030203888A1 (en) | 2001-06-06 | 2003-10-30 | Boyle Ross William | Chromophores |
JP3931236B2 (ja) | 2003-07-09 | 2007-06-13 | 独立行政法人情報通信研究機構 | 基板上のポテンシャル特異点を用いたナノデバイスの製造方法 |
KR101330431B1 (ko) * | 2003-09-11 | 2013-11-20 | 테라노스, 인코포레이티드 | 피분석물의 모니터링 및 약물 전달을 위한 의료 기기 |
WO2006015299A2 (en) * | 2004-07-30 | 2006-02-09 | Microchips, Inc. | Multi-reservoir device for transdermal drug delivery and sensing |
US20060173514A1 (en) * | 2005-02-02 | 2006-08-03 | Advanced Photodynamic Technologies, Inc. | Wound treatment device for photodynamic therapy and method of using same |
US7486977B2 (en) * | 2005-10-27 | 2009-02-03 | Smiths Medical Pm, Inc. | Single use pulse oximeter |
US7499739B2 (en) * | 2005-10-27 | 2009-03-03 | Smiths Medical Pm, Inc. | Single use pulse oximeter |
WO2007081811A2 (en) | 2006-01-04 | 2007-07-19 | The Trustees Of The University Of Pennsylvania | Oxygen sensor for internal monitoring of tissue oxygen in vivo |
US7862598B2 (en) | 2007-10-30 | 2011-01-04 | The Invention Science Fund I, Llc | Devices and systems that deliver nitric oxide |
JP2009162871A (ja) | 2007-12-28 | 2009-07-23 | Fujifilm Corp | 感光性組成物、フォトスペーサー及びフォトスペーサーの製造方法、保護膜、着色パターン、表示装置用基板、並びに表示装置 |
US20120135973A1 (en) | 2010-09-08 | 2012-05-31 | Southern Illinois University Edwardsville | Method for treating chronic pain |
EP2820397A4 (en) | 2012-02-27 | 2015-09-09 | Sergei Vinogradov | IMPROVED PHOSPHORESCENT MOLECULES FOR MEASURING OXYGEN AND IMAGING METHODS |
EP2872877B1 (en) | 2012-07-10 | 2023-05-24 | The General Hospital Corporation | System and method for monitoring and treating a surface of a subject |
US9375494B2 (en) * | 2013-03-14 | 2016-06-28 | Profusa, Inc. | Oxygen sensors |
-
2013
- 2013-07-10 EP EP13817635.9A patent/EP2872877B1/en active Active
- 2013-07-10 ES ES13817635T patent/ES2957540T3/es active Active
- 2013-07-10 US US14/413,571 patent/US10016164B2/en active Active
- 2013-07-10 DK DK13817635.9T patent/DK2872877T3/da active
- 2013-07-10 JP JP2015521766A patent/JP6321004B2/ja active Active
- 2013-07-10 WO PCT/US2013/049847 patent/WO2014011724A1/en active Application Filing
- 2013-07-10 FI FIEP13817635.9T patent/FI2872877T3/fi active
-
2017
- 2017-08-23 US US15/684,040 patent/US10039842B2/en active Active
-
2018
- 2018-08-03 US US16/054,028 patent/US10905780B2/en active Active
-
2020
- 2020-02-11 US US16/787,480 patent/US11253613B2/en active Active
-
2022
- 2022-01-25 US US17/583,997 patent/US20220257797A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH067423A (ja) * | 1992-03-12 | 1994-01-18 | Atrix Lab Inc | 生分解性フィルム被覆材及びその製造方法 |
JP2000517417A (ja) * | 1996-07-22 | 2000-12-26 | ノバルティス アクチエンゲゼルシャフト | 酸素オプトロードのための光感受性組成物 |
JP2000292354A (ja) * | 1999-03-29 | 2000-10-20 | Avl Medical Instr Ag | 局所的な測定量の分布を定量的に測定するための装置 |
JP2003516795A (ja) * | 1999-12-14 | 2003-05-20 | エフ・ホフマン・ラ・ロッシュ・アー・ゲー | 測定パラメータの局所的分布を測定するための方法および装置 |
JP2005501256A (ja) * | 2001-08-22 | 2005-01-13 | スリーエム イノベイティブ プロパティズ カンパニー | 蛍光ベースの酸素センサシステム |
JP2009506878A (ja) * | 2005-09-07 | 2009-02-19 | タイコ ヘルスケア グループ リミテッド パートナーシップ | マイクロポンプを有する自蔵創傷手当て |
WO2012010238A1 (en) * | 2010-07-17 | 2012-01-26 | Merck Patent Gmbh | Enhancement of penetration and action |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016090505A (ja) * | 2014-11-10 | 2016-05-23 | 国立大学法人横浜国立大学 | センサー装置、生体分子視覚化装置およびセンシング方法 |
JP2017181211A (ja) * | 2016-03-29 | 2017-10-05 | 株式会社カテラ | 光学的経皮酸素センサ及びこれを用いた経皮酸素濃度測定装置 |
JP2019520114A (ja) * | 2016-05-13 | 2019-07-18 | ザ ジェネラル ホスピタル コーポレイション | 光経皮酸素モニタリングのシステム及び方法 |
JP7109377B2 (ja) | 2016-05-13 | 2022-07-29 | ザ ジェネラル ホスピタル コーポレイション | 光経皮酸素モニタリングのシステム及び方法 |
KR20220029073A (ko) * | 2020-09-01 | 2022-03-08 | (주) 에이슨 | 유연 경피성 산소 분압센서 |
KR102405616B1 (ko) * | 2020-09-01 | 2022-06-08 | (주) 에이슨 | 유연 경피성 산소 분압센서 |
US11607157B2 (en) | 2020-09-01 | 2023-03-21 | A-sen Company | Flexible transcutaneous oxygen partial pressure sensor |
Also Published As
Publication number | Publication date |
---|---|
US11253613B2 (en) | 2022-02-22 |
JP6321004B2 (ja) | 2018-05-09 |
US20220257797A1 (en) | 2022-08-18 |
FI2872877T3 (fi) | 2023-08-18 |
DK2872877T3 (da) | 2023-08-21 |
US20150182166A1 (en) | 2015-07-02 |
US20170348437A1 (en) | 2017-12-07 |
ES2957540T3 (es) | 2024-01-22 |
US10016164B2 (en) | 2018-07-10 |
WO2014011724A1 (en) | 2014-01-16 |
US10039842B2 (en) | 2018-08-07 |
EP2872877B1 (en) | 2023-05-24 |
US20180344878A1 (en) | 2018-12-06 |
EP2872877A1 (en) | 2015-05-20 |
US20200171172A1 (en) | 2020-06-04 |
EP2872877A4 (en) | 2016-04-13 |
US10905780B2 (en) | 2021-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6321004B2 (ja) | 対象のモニタリングと表面処理のためのシステムおよび方法 | |
CN105530867B (zh) | 用于生物感测分析物的体内保护的药物洗脱 | |
Donnelly et al. | Microneedle-mediated intradermal delivery of 5-aminolevulinic acid: potential for enhanced topical photodynamic therapy | |
JP2019184617A (ja) | 組織酸素化の測定用の器具、システムおよびメソッド | |
US8560059B2 (en) | System and methods for optical sensing and drug delivery using microneedles | |
Ullah et al. | Microneedle array with a pH-responsive polymer coating and its application in smart drug delivery for wound healing | |
JP2012505706A (ja) | 自己調整式光子治療介入の方法およびデバイス | |
PT1213037E (pt) | Método para monitorização facilitada não invasiva de oxigénio | |
US9789206B2 (en) | Compounds, systems, and methods for monitoring and treating a surface of a subject | |
EP3019854B1 (en) | Compounds, systems, and methods for monitoring and treating a surface of a subject | |
JP2006525804A (ja) | 酵素活性化に関する光学式検出器 | |
Howells et al. | Microneedle array‐based platforms for future theranostic applications | |
WO2022051423A1 (en) | Systems and methods for monitoring an analyte or parameter for a patient | |
Gupta et al. | Recovery of skin barrier properties after sonication in human subjects | |
Chen et al. | Latest development and versatile applications of highly integrating drug delivery patch | |
JP7109377B2 (ja) | 光経皮酸素モニタリングのシステム及び方法 | |
RU2280482C1 (ru) | Способ эндоскопического гемостаза | |
Covington et al. | Ultrasound-mediated oxygen delivery to lower extremity wounds | |
CA3120776A1 (en) | Reduction of in vivo analyte signal degradation using multiple metals | |
CA3118592A1 (en) | Drug eluting matrix on analyte indicator | |
TW201728352A (zh) | 藥物釋放與檢測裝置、藥物釋放與檢測裝置的操作方法以及偵測螢光物方法 | |
GUPTA et al. | d Clinical Note |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160607 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170317 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170425 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170714 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170920 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171024 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20180125 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180306 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180404 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6321004 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |